Figure 7. Therapy with Ad-TIMP-2, radiation, and Cisplatin of SCC-1 tumor xenografts.

Nude mice were inoculated with SCC-1 tumor tissue s.c. in the flank. Treatment started once the tumors were 6–8 mm in diameter. Mice were randomly divided into groups of 7 mice to receive different treatments: (1) Ad-TIMP-2 + Ad Wt 300 + XRT + Cisplatin; (2) Ad-TIMP-2 + Ad Wt 300 + XRT; (3) Ad-TIMP-2 + Ad Wt 300; (4) XRT; (5) XRT + Cisplatin; (6) Cisplatin; (7) Ad-TIMP-2 + Ad Wt 300 + Cisplatin; (8) Ad Wt 300; and (9) untreated control. Animals injected with virus received 1 × 10⁸ particles in 50 µl of Ad-TIMP-2 and Ad Wt 300 with a microsyringe for three separate needle passes. Animals receiving virus were injected intratumorally on days 2 and 8 after tumor implantation. Animals in the radiation group received 8 Gy of ⁶⁰Co radiation to the tumor mass divided into four 2 Gy fractions on days 0, 4, 8, and 12. Animals received 4 i.p. doses of Cisplatin (3 mg/kg) 1 h before each fraction of radiation. The triple treatment group (Ad-TIMP-2 + Ad Wt 300 + XRT + Cisplatin) had the highest growth delay followed by the two viruses + XRT group which fared better than XRT alone, Cisplatin alone, virus alone, and untreated control groups. The triple treatment group was significantly different than the control group (P=0.001). Error bars were included on alternate data points.